Wegovy weight loss pill now available in UK - here's what you need to know
Novo Nordisk's oral weight-loss drug, Rybelsus (semaglutide), is now privately available in UK pharmacies, offering a pill alternative to the popular Wegovy injection. This expansion provides a more accessible option for patients seeking weight management, potentially broadening Novo Nordisk's market penetration in the UK.
Novo Nordisk, the pharmaceutical giant behind the blockbuster weight-loss injection Wegovy, has made its oral semaglutide drug, Rybelsus (often used off-label for weight management, though its primary indication is type 2 diabetes), privately available in UK pharmacies. This move significantly expands access to GLP-1 agonists for weight loss in the UK, as patients no longer require a prescription for the injectable version to access a semaglutide product.
Rybelsus offers a daily pill alternative to the weekly Wegovy injection, which has seen immense demand globally. While Rybelsus is not specifically licensed for weight loss in the UK, its active ingredient, semaglutide, is the same as Wegovy, making it a viable option for private prescriptions for weight management under a doctor's guidance. This development follows previous supply constraints on Wegovy in the UK, which limited its widespread availability.
The introduction of an oral semaglutide option in the UK market could further solidify Novo Nordisk's dominant position in the rapidly expanding weight-loss drug sector. It addresses a segment of the population preferring pills over injections and could alleviate some pressure on Wegovy supply chains by diversifying product offerings. The market will be watching how this impacts patient uptake and overall sales figures for Novo Nordisk in the region, especially given the company's strong revenue growth projections.
Novo Nordisk's oral semaglutide (Rybelsus) is now available in the UK, raising questions about whether this expands their market share or cannibalizes existing Wegovy sales.
The private availability of oral semaglutide in the UK significantly expands Novo Nordisk's addressable market for weight management, offering a more convenient option for many patients. While Rybelsus is not officially licensed for weight loss, its active ingredient is identical to Wegovy, and its private availability sidesteps previous supply constraints, suggesting a net positive for NVO's revenue trajectory, projected at +6.4% YoY.
Risk of significant cannibalization of Wegovy sales if patients switch to the oral form, or if supply chain issues for Rybelsus emerge. Increased competition from other GLP-1 agonists also poses a threat.
CoverageSource: BBC Business · Published here MON, JUL 6 · 7:09 AM ET · the only report in this recordHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
The availability of an oral semaglutide option in the UK expands Novo Nordisk's total market reach by appealing to patients who prefer pills over injections, adding to an already robust revenue growth projected at +6.4% YoY.
The primary bear case is potential cannibalization, where patients who would have used Wegovy switch to the oral Rybelsus, limiting the net addition to Novo Nordisk's overall GLP-1 revenue in the UK market.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →